The significance of Ki-67/MIB-1 labeling index in human meningiomas: A literature study

Pathology Research and Practice

Volumn 206, Issue 12, 2010, Pages 810-815

  Abry, Ellen ^a   Thomassen, Ingrid Ø ^a   Salvesen, Øyvind O ^b   Torp, Sverre H ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain tumors; Diagnosis; Immunohistochemistry; Prognosis; Proliferation; Review

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HUMAN; LABELING INDEX; MENINGIOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MENINGEAL NEOPLASMS; MENINGIOMA; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649745157     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.09.002     Document Type: Article

References (71)

1. Abramovich C.M., Prayson R.A. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum. Pathol. 1998, 29:1420-1427.
2. Abramovich C.M., Prayson R.A. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch. Pathol. Lab. Med. 1999, 123:793-800.
3. Alama A., Barbieri F., Spaziante R., Bruzzo C., Dadati P., Dorcaratto A., et al. Significance of cyclin D1 expression in meningiomas: a preliminary study. J. Clin. Neurosci. 2007, 14:355-358.
4. Amatya V.J., Takeshima Y., Sugiyama K., Kurisu K., Nishisaka T., Fukuhara T., et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum. Pathol. 2001, 32:970-975.
5. Antinheimo J., Haapasalo H., Haltia M., Tatagiba M., Thomas S., Brandis A., et al. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J. Neurosurg. 1997, 87:610-614.
6. Barresi V., Cerasoli S., Paioli G., Vitarelli E., Giuffre G., Guiducci G., et al. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol. 2006, 112:617-626.
7. Baumgartner J.E., Sorenson J.M. Meningioma in the pediatric population. J. Neurooncol. 1996, 29:223-228.
8. Bozkurt S.U., Ayan E., Bolukbasi F., Elmaci I., Pamir N., Sav A. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS 2009, 117:651-659.
9. Cattoretti G., Becker M.H., Key G., Duchrow M., Schluter C., Galle J., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992, 168:357-363.
10. Ferraraccio F., Accardo M., Giangaspero F., Cuccurullo L. Recurrent and atypical meningiomas - a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining. Clin. Neuropathol. 2003, 22:187-192.
11. Grzybicki D.M., Liu Y., Moore S.A., Brown H.G., Silverman J.F., D'Amico F., et al. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 2001, 92:2720-2726.
12. Ho D.M., Hsu C.Y., Ting L.T., Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002, 94:1538-1547.
13. Hsu D.W., Efird J.T., Hedley-Whyte E.T. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J. Neurosurg. 1997, 86:113-120.
14. Hsu D.W., Efird J.T., Hedley-Whyte E.T. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol. Appl. Neurobiol. 1998, 24:441-452.
15. Ishimaru K., Hirano H., Yamahata H., Takeshima H., Niiro M., Kuratsu J. The expression of tissue factor correlates with proliferative ability in meningioma. Oncol. Rep. 2003, 10:1133-1137.
16. Kakinuma K., Tanaka R., Onda K., Takahashi H. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time. Acta Neurochir. (Wien) 1998, 140:26-31. (discussion 31-22).
17. Kalala J.P., Caemaert J., De Ridder L. Primary resected meningiomas: relapses and proliferation markers. In Vivo 2004, 18:411-416.
18. Karamitopoulou E., Perentes E., Tolnay M., Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum. Pathol. 1998, 29:140-145.
19. Kasuya H., Kubo O., Tanaka M., Amano K., Kato K., Hori T. Clinical and radiological features related to the growth potential of meningioma. Neurosurg. Rev. 2006, 29:293-296. (discussion 296-297).
20. Kim Y.J., Ketter R., Steudel W.I., Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am. J. Clin. Pathol. 2007, 128:118-125.
21. Kim Y.J., Romeike B.F., Uszkoreit J., Feiden W. Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas. Clin. Neuropathol. 2006, 25:67-73.
22. Kleihues P., Burger P.C., Scheithauer B.W. The new WHO classification of brain tumours. Brain Pathol. 1993, 3:255-268.
23. Kolles H., Niedermayer I., Schmitt C., Henn W., Feld R., Steudel W.I., et al. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics. Acta Neurochir. (Wien) 1995, 137:174-181.
24. Konstantinidou A.E., Korkolopoulou P., Kavantzas N., Mahera H., Thymara I., Kotsiakis X., et al. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol. Histopathol. 2003, 18:67-74.
25. Korhonen K., Salminen T., Raitanen J., Auvinen A., Isola J., Haapasalo H. Female predominance in meningiomas cannot be explained by differences in progesterone, estrogen, or androgen receptor expression. J. Neurooncol. 2006, 80:1-7.
26. Korshunov A., Shishkina L., Golanov A. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int. J. Cancer 2003, 104:728-734.
27. Kunishio K., Morisaki K., Matsumoto Y., Nagao S. DNA topoisomerase IIalpha protein and mRNA expression in intracranial meningiomas. Brain Tumor Pathol. 2000, 17:105-110.
28. Langford L.A., Cooksley C.S., DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum. Pathol. 1996, 27:350-354.
29. Lanzafame S., Torrisi A., Barbagallo G., Emmanuele C., Alberio N., Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol. Res. Pract. 2000, 196:483-488.
30. Louis D.N., Scheithauer B., Budka H., Von Deimling A., Kepes J.J. Meningiomas. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Nervous System 2000, 176-184. IARC, Lyon. 3rd ed.
31. Madsen C., Schrøder H.D. Ki-67 immunoreactivity in meningiomas - determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. Clin. Neuropathol. 1997, 16:137-142.
32. Maes L., Lippens E., Kalala J.P., de Ridder L. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 2005, 38:3-12.
33. Maier H., Wanschitz J., Sedivy R., Rössler K., Ofner D., Budka H. Proliferation and DNA fragmentation in meningioma subtypes. Neuropathol. Appl. Neurobiol. 1997, 23:496-5056.
34. Maiuri F., De Caro Mdel B., Esposito F., Cappabianca P., Strazzullo V., Pettinato G., et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J. Neurooncol. 2007, 82:63-68.
35. Matsuno A., Fujimaki T., Sasaki T., Nagashima T., Ide T., Asai A., et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol. 1996, 91:504-510.
36. Mawrin C., Sasse T., Kirches E., Kropf S., Schneider T., Grimm C., et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin. Cancer Res. 2005, 11:4074-4082.
37. Møller M.L., Brændstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J. Neurooncol. 1997, 34:241-246.
38. Moradi A., Semnani V., Djam H., Tajodini A., Zali A.R., Ghaemi K., et al. Pathodiagnostic parameters for meningioma grading. J. Clin. Neurosci. 2008, 15:1370-1375.
39. Morimura T., Kitz K., Budka H. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67. Acta Neuropathol. 1989, 77:276-282.
40. Murakami M., Hashimoto N., Takahashi Y., Hosokawa Y., Inazawa J., Mineura K. A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet. Cytogenet. 2003, 140:99-106.
41. Nagashima G., Aoyagi M., Wakimoto H., Tamaki M., Ohno K., Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 1995, 37:478-482. (discussion 483).
42. Nakabayashi H., Shimizu K., Hara M. Prognostic significance of cyclin a expression in meningiomas. Appl. Immunohistochem. Mol. Morphol. 2003, 11:9-14.
43. Nakasu S., Li D.H., Okabe H., Nakajima M., Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am. J. Surg. Pathol. 2001, 25:472-478.
44. Okada M., Miyake K., Matsumoto Y., Kawai N., Kunishio K., Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J. Neurooncol. 2004, 66:29-37.
45. Omulecka A., Papierz W., Nawrocka-Kunecka A., Lewy-Trenda I. Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006, 44:111-115.
46. Ozen O., Demirhan B., Altinors N. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin. Neuropathol. 2005, 24:219-224.
47. Perry A., Louis D.N., Scheithauer B., Budka H., Von Deimling A. Meningiomas. WHO Classification of Tumours of the Central Nervous System 2007, 164-172. IARC, Lyon. 4th ed.
48. Perry A., Stafford S.L., Scheithauer B.W., Suman V.J., Lohse C.M. Meningioma grading: an analysis of histologic parameters. Am. J. Surg. Pathol. 1997, 21:1455-1465.
49. Perry A., Stafford S.L., Scheithauer B.W., Suman V.J., Lohse C.M. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998, 82:2262-2269.
50. Pfisterer W.K., Coons S.W., Aboul-Enein F., Hendricks W.P., Scheck A.C., Preul M.C. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J. Neurooncol. 2008, 87:43-50.
51. Prayson R.A. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv. Anat. Pathol. 2005, 12:144-148.
52. Roessler K., Gatterbauer B., Kitz K. Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol. Res. 2002, 24:241-243.
53. Roser F., Nakamura M., Bellinzona M., Ritz R., Ostertag H., Tatagiba M.S. Proliferation potential of spinal meningiomas. Eur. Spine J. 2006, 15:211-215.
54. Roser F., Samii M., Ostertag H., Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir. (Wien) 2004, 146:37-44. (discussion 44).
55. Sandberg D.I., Edgar M.A., Resch L., Rutka J.T., Becker L.E., Souweidane M.M. MIB-1 staining index of pediatric meningiomas. Neurosurgery 2001, 48:590-595. (discussion 595-597).
56. Shimada S., Ishizawa K., Hirose T. Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy. Pathol. Int. 2005, 55:1-7.
57. Smith J.S., Lal A., Harmon-Smith M., Bollen A.W., McDermott M.W. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J. Neurosurg. 2007, 106:1034-1040.
58. Striepecke E., Handt S., Weis J., Koch A., Cremerius U., Reineke T., et al. Correlation of histology, cytogenetics and proliferation fraction (Ki-67 and PCNA) quantitated by image analysis in meningiomas. Pathol. Res. Pract. 1996, 192:816-824.
59. Takahashi J.A., Ueba T., Hashimoto N., Nakashima Y., Katsuki N. The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg. Neurol. 2004, 61:149-155. (discussion 155-146).
60. Takei H., Buckleair L.W., Powell S.Z. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Neuropathology 2008, 28:62-68.
61. Takeuchi H., Kubota T., Kabuto M., Kitai R., Nozaki J., Yamashita J. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg. Neurol. 1997, 48:501-506.
62. Terzi A., Saglam E.A., Barak A., Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol. Res. Pract. 2008, 204:305-314.
63. Torp S.H., Lindboe C.F., Granli U.S., Moen T.M., Nordtomme T. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin. Neuropathol. 2001, 20:190-195.
64. Torp S.H., Lindboe C.F., Gronberg B.H., Lydersen S., Sundstrom S. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin. Neuropathol. 2005, 24:170-174.
65. Tyagi A., Chakrabarty A., Franks A. MIB1 proliferation index in meningiomas: does it predict recurrence? A clinicopathological study. Br. J. Neurosurg. 2004, 18:357-361.
66. Utsuki S., Oka H., Sato Y., Kawano N., Tsuchiya B., Kobayashi I., et al. Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. Clin. Neuropathol. 2005, 24:8-12.
67. Uzum N., Ataoglu G.A. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori 2008, 94:389-397.
68. Vankalakunti M., Vasishta R.K., Das Radotra B., Khosla V.K. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 2007, 27:407-412.
69. Wolfsberger S., Doostkam S., Boecher-Schwarz H.G., Roessler K., van Trotsenburg M., Hainfellner J.A., et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg. Rev. 2004, 27:238-245.
70. Yamasaki F., Yoshioka H., Hama S., Sugiyama K., Arita K., Kurisu K. Recurrence of meningiomas. Cancer 2000, 89:1102-1110.
71. Yang S.Y., Park C.K., Park S.H., Kim D.G., Chung Y.S., Jung H.W. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J. Neurol. Neurosurg. Psychiatry 2008, 79:574-580.